Repligen (RGEN) Stock Price
Repligen Price
Revenue has compounded at 23.2% per year over the past 19 years to 738.26 M USD. Earnings per share have declined at 1.8% per year over the last 18 years. Repligen's net margin stands at 6.6%, down from 19.1% several years earlier. Analysts set a median price target of 195.84 USD, implying 16.8% above the current price. Of 28 analysts, 23 rate the stock a buy — an overall Buy consensus. The stock trades about 63% above its 52-week low.
Repligen stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Repligen over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Repligen stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Repligen's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Repligen Price |
|---|---|
| 9/4/2026 | 167.60 USD |
| 9/3/2026 | 169.61 USD |
| 9/2/2026 | 172.94 USD |
| 9/1/2026 | 170.02 USD |
| 8/31/2026 | 180.98 USD |
| 8/30/2026 | 178.08 USD |
| 8/28/2026 | 177.07 USD |
| 8/27/2026 | 181.66 USD |
| 8/26/2026 | 180.30 USD |
| 8/25/2026 | 181.69 USD |
| 8/24/2026 | 181.98 USD |
| 8/21/2026 | 181.13 USD |
| 8/20/2026 | 180.29 USD |
| 8/19/2026 | 175.15 USD |
| 8/18/2026 | 165.43 USD |
| 8/14/2026 | 166.83 USD |
| 8/13/2026 | 167.49 USD |
| 8/12/2026 | 165.70 USD |
| 8/11/2026 | 164.77 USD |
| 8/10/2026 | 163.39 USD |
| 8/7/2026 | 163.90 USD |
| 8/6/2026 | 159.44 USD |
| 8/5/2026 | 155.43 USD |
| 8/4/2026 | 147.02 USD |
| 8/3/2026 | 147.06 USD |
| 7/31/2026 | 141.01 USD |
| 7/30/2026 | 143.60 USD |
| 7/29/2026 | 143.97 USD |
| 7/27/2026 | 132.65 USD |
| 7/23/2026 | 137.60 USD |
Repligen Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Repligen Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB USD |
| EBITB USD |
| EBIT MARGIN% |
| NET INCOMEB USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.08 | 0.10 | 0.14 | 0.19 | 0.27 | 0.37 | 0.67 | 0.80 | 0.64 | 0.63 | 0.74 | 0.83 | 0.96 | 1.12 | 1.25 | 1.44 |
| 31.75 | 25.30 | 35.58 | 37.59 | 39.18 | 35.56 | 83.06 | 19.55 | -20.35 | -0.63 | 16.40 | 12.06 | 16.44 | 15.99 | 12.26 | 14.83 |
| 57.83 | 54.81 | 52.48 | 55.67 | 51.11 | 53.01 | 58.36 | 56.80 | 44.51 | 43.22 | 47.02 | 47.02 | 47.02 | 47.02 | 47.02 | 47.02 |
| 0.05 | 0.06 | 0.07 | 0.11 | 0.14 | 0.19 | 0.39 | 0.46 | 0.28 | 0.27 | 0.35 | 0.39 | 0.45 | 0.53 | 0.59 | 0.68 |
| 0.01 | 0.02 | 0.01 | 0.03 | 0.04 | 0.08 | 0.17 | 0.22 | 0.06 | -0.04 | 0.08 | 0.16 | 0.21 | 0.26 | 0.32 | 0.39 |
| 15.66 | 14.42 | 9.22 | 12.89 | 14.81 | 22.13 | 24.93 | 27.97 | 8.78 | -5.52 | 11.11 | 19.71 | 21.39 | 23.63 | 25.76 | 27.36 |
| 0.01 | 0.01 | 0.03 | 0.02 | 0.02 | 0.06 | 0.13 | 0.19 | 0.04 | -0.03 | 0.05 | 0.12 | 0.15 | 0.19 | 0.24 | 0.30 |
| 12.50 | 22.22 | 154.55 | -42.86 | 31.25 | 180.95 | 116.95 | 44.53 | -77.84 | -160.98 | -292.00 | 139.58 | 26.96 | 30.82 | 27.23 | 23.46 |
| 33.58 | 34.37 | 44.39 | 46.29 | 52.98 | 55.02 | 57.72 | 57.11 | 55.82 | 56.06 | 56.52 | 56.52 | 56.52 | 56.52 | 56.52 | 56.52 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Repligen generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Repligen retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Repligen's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Repligen has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Repligen's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Repligen stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Repligen Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Repligen business model & stock analysis
Repligen SWOT Analysis
Strengths
Repligen Corp benefits from a diversified product portfolio, offering a range of high-quality bioprocessing products and technologies.
The company has successfully established strategic partnerships with industry leaders, allowing for increased market reach and access to new customers.
Repligen Corp demonstrates strong research and development capabilities, continually innovating to meet the evolving needs of the bioprocessing industry.
Weaknesses
The company's revenue is heavily reliant on a few major customers, posing a risk if any of these customers reduce their purchases or switch to competitors.
Repligen Corp operates in a highly regulated industry, facing challenges in ensuring compliance with various governmental regulations and standards.
Opportunities
The rapidly growing biopharmaceutical market presents significant opportunities for Repligen Corp to expand its customer base and increase revenue.
Advancements in bioprocessing technologies open doors for the development of new products and services, allowing Repligen Corp to stay competitive and meet future industry demands.
Threats
The bioprocessing industry is highly competitive, with the presence of both well-established companies and emerging players, potentially leading to price pressures and market share challenges for Repligen Corp.
Global economic conditions and fluctuations may impact the demand for bioprocessing products, potentially affecting Repligen Corp's sales and profitability.
Repligen Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Repligen Segments
Repligen Revenue by Segment
3 Years
5 Years
Max
Details
Repligen Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Repligen historical P/E ratio, EBIT multiple, and P/S ratio
Repligen annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Repligen shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Repligen forecasts and price targets in September 2026
Analyst Price Targets 2026Repligen Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 7/30/2026 | Maintained | Overweight | 55 | |
| 7/29/2026 | Maintained | Overweight | 59 | |
| 7/7/2026 | Upgrade | HoldBuy | 72 | |
| 7/6/2026 | Maintained | Outperform | 62 | |
| 6/3/2026 | Maintained | Buy | – | |
| 5/6/2026 | Maintained | Overweight | 59 | |
| 5/6/2026 | Maintained | Overweight | 57 | |
| 4/20/2026 | Maintained | Hold | 64 | |
| 4/14/2026 | Maintained | Overweight | 57 | |
| 4/6/2026 | Maintained | Outperform | 62 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Repligen Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/4/2026 | 0.46USD | - | 205.33 MUSD | - | 2026 Q2 |
| 5/5/2026 | 0.39USD | - | 196.12 MUSD | - | 2026 Q1 |
| 2/25/2026 | 0.45USD | - | 196.77 MUSD | - | 2025 Q4 |
| 11/12/2024 | 0.34USD | - | 156.29 MUSD | - | 2024 Q3 |
| 4/30/2024 | 0.38USD | - | 161.50 MUSD | - | 2024 Q1 |
| 2/20/2024 | 0.33USD | - | 159.76 MUSD | - | 2023 Q4 |
| 8/2/2022 | 0.73USD | - | 192.17 MUSD | - | 2022 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Repligen stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Repligen shareholder structure
| % | Name |
|---|---|
10.71394% | |
8.72078% | |
5.16078% | |
4.95911% | |
4.28430% | |
4.12088% |
Repligen Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
12.40% | SEC ↗ | |
11.18% | SEC ↗ | |
11.18% | SEC ↗ | |
10.20% | SEC ↗ | |
9.30% | SEC ↗ | |
8.89% | SEC ↗ | |
8.20% | SEC ↗ | |
7.40% | SEC ↗ | |
6.65% | SEC ↗ | |
5.73% | SEC ↗ |
Repligen Executives and Management Board
13 members · avg. age 62 · 23 % women
Mr. Olivier Loeillot (55)
President, Chief Executive Officer, Director · since 2023
7.18 M USD
Management
Mr. James Bylund (62)
Chief Operating Officer
Mr. Jason Garland (51)
Chief Financial Officer
Mr. Ralf Kuriyel (67)
Senior Vice President - Research and Development
Board of Directors
Mr. Tony Hunt (61)
Executive Chairman of the Board · since 2014
Ms. Margaret Pax (65)
Independent Director
Ms. Karen Dawes (73)
Lead Independent Director · since 2005
Mr. Glenn Muir (66)
Independent Director
Mr. Nicolas Barthelemy (59)
Independent Director
Dr. Martin Madaus (65)
Independent Director
Frequently asked questions about Repligen
Repligen Corp's business model is centered around being a leading provider of products and services for the bioprocessing industry. The company focuses on developing and supplying innovative solutions that enhance the production of biologic drugs. Repligen offers a range of products including bioreactors, filtration systems, chromatography resins, and pre-packed columns. By offering these high-quality and reliable solutions, Repligen aims to support biopharmaceutical companies in improving their manufacturing processes, increasing productivity, and ensuring the quality of their products. Repligen Corp is dedicated to driving advancements in the bioprocessing industry by delivering exceptional products and services to its customers.
Repligen Corp is primarily active in the biotechnology and life sciences industries.
Some of the main competitors of Repligen Corp in the market include Thermo Fisher Scientific, Merck KGaA, Danaher Corporation, and GE Healthcare.
Repligen Corp is a prominent bioprocessing company with a rich history. Founded in 1981, Repligen initially focused on the development of diagnostic products and later expanded its scope to include bioprocessing technologies. Over the years, the company has made significant contributions to the life sciences industry, offering innovative solutions for biomanufacturing needs. Today, Repligen is recognized for its high-quality products and services, serving customers globally. With a commitment to advancing bioprocessing efficiency and productivity, Repligen continues to drive innovation in the field, supporting the development and manufacturing of biologics.
Repligen Corp has achieved several significant milestones. The company successfully completed the acquisition of Spectrum Laboratories in 2012, expanding its product portfolio and enhancing its market presence. In 2014, Repligen received FDA approval for its flagship bioprocessing product, Protein A, which revolutionized the purification of monoclonal antibodies. The company continued its growth by acquiring the business unit of Novavax Inc. in 2015, strengthening its position in the bioprocessing market. Repligen Corp also reached a partnership agreement with Navigo Proteins GmbH in 2019, allowing the development of new affinity ligands. These achievements demonstrate Repligen Corp's dedication to innovation and market leadership.
Repligen Corp is primarily present in several countries and regions. These include the United States, Europe, and Asia.
Repligen Corp is a leading bioprocessing company committed to enhancing biologic drug manufacturing processes. The company's corporate philosophy revolves around key values such as innovation, quality, and collaboration. Repligen Corp strives to provide cutting-edge solutions to improve productivity, efficiency, and consistency in bioproduction through its advanced technologies and expertise. With a focus on customer satisfaction and a passion for advancing bioprocessing technologies, Repligen Corp aims to empower customers and contribute to making biologic medicines more accessible for patients worldwide.
Analysts currently set an average price target of 194.44 USD for the Repligen stock (median: 195.84 USD), implying +16.0 % versus the latest price. The consensus is based on 28 analyst ratings.
28 analysts currently rate the Repligen stock: 23 recommend buying, 5 holding and 0 selling. For 2026, analysts expect Repligen to generate revenue of 827.45 M USD and earnings per share of 2.04 USD.
Converted at the current exchange rate, the Repligen share trades at 144.20 EUR (167.60 USD).
The Repligen share (RGEN) is listed on 5 stock exchanges, including: NASDAQ (RGEN), Frankfurt (RGN.F), München (RGN.MU), Düsseldorf (RGN.DU), SIX (Zürich) (RGN.SW).
Repligen Corp is a leading biotech company specializing in the research, development, and manufacturing of products for bioproduction and cell therapy. The company was founded in 1981 and is headquartered in Waltham, Massachusetts. Repligen Corp's business model is based on four different divisions: bioproduction, chromatography, short-term culture media, and cell therapy. These divisions offer a wide range of products for the research and development community as well as the biopharmaceutical industry. The bioproduction division of Repligen Corp offers a variety of products for the production of recombinant proteins, antibodies, and other therapeutics. These include HGGE and Protein-A affinity resins, the TangenX® membrane separation portfolio, and the XCell™ ATF system for perfusion. The chromatography division of Repligen Corp offers a wide range of products for the purification of proteins and other biologics. These include protein-A affinity resins, reversed-phase resins, HIC and ion exchange resins, and more. The short-term culture media division of Repligen Corp specializes in the development of media for cell cultivation. These include the OptiCHO™, OptiPEAK TiterMAX®, and CellBoost™ portfolios. The cell therapy division of Repligen Corp offers strictly regulated products for clinical applications in cell therapy. These include Syntheglas™ peptides and SAVI™ cell therapy products for the treatment of inflammatory diseases in the gastrointestinal tract. Repligen Corp also offers services and support for its products, including technical consulting and support as well as product training. The company works closely with its customers to ensure that its products meet the specific requirements of the research and biopharmaceutical industry. Overall, Repligen Corp has a strong business model based on the development of innovative products for bioproduction and cell therapy. The company is committed to advancing the development of its products and actively participating in the expansion of the bioproduction industry. Answer: Repligen Corp is a biotech company specializing in the research, development, and manufacturing of products for bioproduction and cell therapy. They offer a range of products for protein production, protein purification, cell cultivation, and cell therapy. The company provides services, support, and product training and aims to contribute to the growth of the bioproduction industry.
The expected revenue of Repligen is 827.45 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Repligen is 115.30 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Repligen is currently 82.16. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Repligen stock.
The price-to-sales ratio (P/S) of Repligen is currently 11.45. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Repligen stock.
The Eulerpool Quality Score for Repligen is 4/10.
The ISIN of Repligen is US7599161095. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Repligen is 870980. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Repligen is RGEN. The ticker symbol is used to trade Repligen shares on the stock exchange.
Repligen paid dividends every year for the past 0 years.
Repligen is assigned to the 'Health' sector.
The dividends of Repligen are distributed in USD.
Repligen stock
Repligen Peer Group
Repligen Ticker
Repligen FIGI
All fundamentals and in-depth analysis of Repligen
Our stock analysis for Repligen stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Repligen. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.